Odyssean LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX

Odyssean LLC lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 211.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,638 shares of the company’s stock after buying an additional 42,527 shares during the period. Vaxcyte makes up 0.6% of Odyssean LLC’s portfolio, making the stock its 4th biggest position. Odyssean LLC’s holdings in Vaxcyte were worth $3,641,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in Vaxcyte by 115.2% during the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock valued at $1,113,000 after acquiring an additional 15,774 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Vaxcyte during the 1st quarter valued at about $219,000. Caxton Associates LLP bought a new stake in shares of Vaxcyte in the first quarter worth approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Vaxcyte by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after acquiring an additional 41,034 shares during the period. Finally, Cetera Investment Advisers lifted its position in Vaxcyte by 13.8% during the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after purchasing an additional 932 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $61.09 on Wednesday. The stock’s 50-day simple moving average is $56.91 and its two-hundred day simple moving average is $55.88. The stock has a market capitalization of $9.09 billion, a price-to-earnings ratio of -8.01 and a beta of 1.23. Vaxcyte, Inc. has a 52-week low of $29.87 and a 52-week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same quarter in the previous year, the business posted ($1.22) EPS. As a group, equities analysts forecast that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

PCVX has been the topic of several research reports. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Finally, Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Vaxcyte has an average rating of “Moderate Buy” and an average target price of $86.00.

Insider Buying and Selling at Vaxcyte

In related news, insider Harpreet S. Dhaliwal sold 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the sale, the insider directly owned 76,756 shares in the company, valued at approximately $4,221,580. The trade was a 18.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $57.28, for a total transaction of $572,800.00. Following the sale, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at approximately $5,979,745.60. This represents a 8.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 120,646 shares of company stock worth $6,570,810. 3.30% of the stock is owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.